MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

(2012) H E Lee et al.   BRITISH JOURNAL OF CANCER

HER2 testing in gastric cancer: a practical approach

(2012) Josef Rüschoff et al.   MODERN PATHOLOGY

MET Expression and Amplification in Patients with Localized Gastric Cancer

(2011) Y. Y. Janjigian et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer

(2011) Yuji Toiyama et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer

(2011) Francesco Graziano et al.   JOURNAL OF CLINICAL ONCOLOGY

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY

Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma

(2008) Sung Bum Cho et al.   PATHOLOGY INTERNATIONAL